Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Preclinical Immunogenicity Assessment of Novel Gene Therapy Capsids in NHP Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Immunogenicity Assessment of Novel Gene Therapy Capsids in NHP Models

CELL & GENE | RNA | BIOLOGICS

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

Translating Capsid Innovation into Clinical Confidence.

Technical Question Franklin Biolabs’ Approach
Why are NHP models the standard for AAV immunogenicity assessment? The immunological homology between non-human primates and humans provides the most predictive data on potential human responses. This includes assessing the impact of pre-existing cross-reactive antibodies and the activation of conserved T-cell epitopes, which are not adequately modeled in lower-order species.
What are the primary goals of an IND-enabling immunogenicity study? The main objective is to fully characterize the vector’s immune profile before human administration. This involves designing a study capable of evaluating both humoral (antibody-mediated) and cellular (T-cell-mediated) responses to the capsid, providing a predictive forecast of the vector’s safety and activity.
How are pre-existing antibodies managed in study design? All NHP cohorts undergo rigorous pre-screening to determine baseline serostatus against the specific AAV serotype. Animals are then selected and stratified based on these results to ensure the study population meets specific criteria, such as being seronegative or having low titers, which isolates the response to the administered vector.
What is the typical monitoring duration for an NHP immunogenicity study? While protocol-dependent, long-term monitoring is standard for gene therapy programs. We typically recommend sample collection schedules that span at least six months, and often longer, to fully characterize the onset, magnitude, and persistence of immune responses post-vector administration.

The clinical viability of a novel adeno-associated virus (AAV) vector is directly linked to its immunogenic profile. A comprehensive preclinical immunogenicity assessment in non-human primate (NHP) models is the definitive method for de-risking a gene therapy candidate ahead of human trials. This process is designed to capture the full spectrum of humoral and cellular immune responses to the capsid, providing data to inform dose selection, predict potential toxicities, and support a successful Investigational New Drug (IND) application.

De-Risking Novel Capsids with Predictive NHP Models

The translatability of a gene therapy program depends on accurately forecasting the human immune response to the vector capsid. NHP models offer the highest predictive value for this assessment due to their immunological similarity to humans. This is particularly relevant when evaluating novel or engineered AAV capsids designed to overcome the limitations of naturally occurring serotypes, such as widespread pre-existing immunity in the human population.

An effective NHP study design isolates the immunogenic properties of the novel capsid itself. This requires meticulous characterization of both the vector and the study cohort to generate unambiguous data for regulatory submission.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Engineering Capsids for Optimized Biodistribution

Recent research highlights the power of rational capsid design to modulate vector properties. For instance, engineering the AAV9 capsid to alter its glycan binding has been shown to successfully reduce liver tropism while enhancing cardiac tissue targeting (PMID: 39001819). This work also revealed significant species-specific differences in glycan presentation between common preclinical models and NHPs.

This finding underscores the necessity of validating engineered capsids in NHP studies. An observed biodistribution profile in one species does not guarantee the same outcome in primates. Verifying tropism and quantifying non-target tissue biodistribution in NHPs is a required step to confirm the vector’s mechanism of action and safety profile.

Foundational NHP Study Design and Conduct

Our studies, conducted in a GxP-compliant, >100,000 sq ft facility, are designed to provide a complete safety profile. Success is built on a foundation of robust study design and execution. This includes:

  • Long-Term Monitoring: In-life observation periods sufficient to capture the full kinetics of an immune response.

  • Comprehensive Sample Collection: Strategic, protocol-defined collection of all relevant matrices, including serum, plasma, and peripheral blood mononuclear cells (PBMCs).

  • Terminal Tissue Collection: Exhaustive tissue harvesting at necropsy to support thorough biodistribution and transgene expression assessments.

  • GxP-Compliant Execution: Meticulous documentation and operational oversight to ensure data integrity for regulatory review.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

Commitment to Animal Welfare and Programmatic Excellence

Executing these complex studies requires an unwavering commitment to the highest standards of animal care. Our programs are designed to exceed regulatory expectations and are built upon a foundation of ethical responsibility.

Our animal welfare strategy incorporates the 3Rs (Reduction, Refinement, and Replacement) and is fully accredited by AAALAC and compliant with USDA guidelines. This operational excellence supports our clients’ accelerated development, contributing to an average 18-24 month IND timeline. Since the Franklin Biolabs brand launch in 2024, programs relying on our preclinical data have maintained a 100% IND success rate, a record established by our core scientific team since 2019.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities